16253392|t|DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
16253392|a|The steroid dehydroepiandrosterone (DHEA) is abundant in men and women and decreases rapidly during aging. Parkinson's disease (PD) is the second most common neurodegenerative disorder just behind Alzheimer. l-3,4-Dihydroxyphenylalanine (l-Dopa) therapy remains the most effective treatment but many patients develop motor complications. This study investigated the acute effect of DHEA alone and with l-Dopa in 12 females monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to model PD. DHEA administration alone improved the mean parkinsonian score at 1, 5 and 15mg/kg in moderately and severely impaired MPTP monkeys and increased blood DHEA concentrations. DHEA with a low dose of l-Dopa increased the l-Dopa effect in moderately and severely impaired MPTP monkeys. DHEA lengthened duration of the effect of the low dose of l-Dopa by 15-45min. DHEA at 1, 5 and 15mg/kg combined with a high dose of l-Dopa did not increase dyskinesias. DHEA could act by reducing inhibitory GABAergic activity in the striatal output pathways. DHEA could also be metabolized into estradiol in the brain and increase acutely dopamine activity.
16253392	0	4	DHEA	Chemical	MESH:D003687
16253392	72	76	MPTP	Chemical	MESH:D015632
16253392	77	84	monkeys	Species	9527
16253392	90	97	steroid	Chemical	MESH:D013256
16253392	98	120	dehydroepiandrosterone	Chemical	MESH:D003687
16253392	122	126	DHEA	Chemical	MESH:D003687
16253392	143	146	men	Species	9606
16253392	151	156	women	Species	9606
16253392	193	212	Parkinson's disease	Disease	MESH:D010300
16253392	214	216	PD	Disease	MESH:D010300
16253392	244	270	neurodegenerative disorder	Disease	MESH:D019636
16253392	283	292	Alzheimer	Disease	MESH:D000544
16253392	294	322	l-3,4-Dihydroxyphenylalanine	Chemical	MESH:D007980
16253392	324	330	l-Dopa	Chemical	MESH:D007980
16253392	386	394	patients	Species	9606
16253392	468	472	DHEA	Chemical	MESH:D003687
16253392	488	494	l-Dopa	Chemical	MESH:D007980
16253392	509	516	monkeys	Species	9527
16253392	531	575	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	Chemical	MESH:D015632
16253392	577	581	MPTP	Chemical	MESH:D015632
16253392	592	594	PD	Disease	MESH:D010300
16253392	596	600	DHEA	Chemical	MESH:D003687
16253392	640	652	parkinsonian	Disease	MESH:D010300
16253392	715	719	MPTP	Chemical	MESH:D015632
16253392	720	727	monkeys	Species	9527
16253392	748	752	DHEA	Chemical	MESH:D003687
16253392	769	773	DHEA	Chemical	MESH:D003687
16253392	793	799	l-Dopa	Chemical	MESH:D007980
16253392	814	820	l-Dopa	Chemical	MESH:D007980
16253392	864	868	MPTP	Chemical	MESH:D015632
16253392	869	876	monkeys	Species	9527
16253392	878	882	DHEA	Chemical	MESH:D003687
16253392	936	942	l-Dopa	Chemical	MESH:D007980
16253392	956	960	DHEA	Chemical	MESH:D003687
16253392	1010	1016	l-Dopa	Chemical	MESH:D007980
16253392	1034	1045	dyskinesias	Disease	MESH:D004409
16253392	1047	1051	DHEA	Chemical	MESH:D003687
16253392	1137	1141	DHEA	Chemical	MESH:D003687
16253392	1173	1182	estradiol	Chemical	MESH:D004958
16253392	1217	1225	dopamine	Chemical	MESH:D004298
16253392	Positive_Correlation	MESH:D003687	MESH:D004298
16253392	Association	MESH:D007980	MESH:D015632
16253392	Positive_Correlation	MESH:D003687	MESH:D013256
16253392	Negative_Correlation	MESH:D015632	MESH:D010300
16253392	Positive_Correlation	MESH:D003687	MESH:D004958
16253392	Cotreatment	MESH:D007980	MESH:D013256
16253392	Negative_Correlation	MESH:D003687	MESH:D015632
16253392	Negative_Correlation	MESH:D007980	MESH:D010300
16253392	Positive_Correlation	MESH:D003687	MESH:D010300
16253392	Positive_Correlation	MESH:D003687	MESH:D007980

